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Abstract
Pulmonary aspiration of gastric refluxate (PAGR) has been demonstrated in association with pulmonary inflammation in
school aged children with Cystic Fibrosis (CF). We sought to determine if similar findings were present in preschool
children. Pepsin was measured in Broncho-alveolar lavage (BAL) fluid collected from clinically stable preschool children
with CF and controls. Elevated pepsin levels were found in a subgroup of children with CF, but this was not found to
be associated with pulmonary infection, pulmonary inflammation or respiratory or gastrointestinal symptoms.
Introduction
Gastro-oesophageal reflux (GOR) is the involuntary passage
of gastric content into the oesophagus. Gastro-oesophageal
reflux disease (GORD) is present when GOR causes adverse
consequences such as pain, failure to thrive or pulmonary
aspiration. The reported prevalence of GORD in CF is be-
tween 35 and 81% and has been associated with reduced
lung function and increased cough in older patients [1, 2].
We have previously demonstrated that PAGR occurs in a
subgroup of school-aged children with CF and is associated
with more pronounced airway inflammation [3].
There has been much focus recently on the detection
of evolving lung disease in preschool children with CF,
where traditional outcome measures are poor and chil-
dren can be largely asymptomatic despite the develop-
ment of irreversible structural lung disease [4, 5]. The
focus of pulmonary management in CF is increasingly
moving towards aggressive prevention of disease, where
possible, rather than solely targeting clinically evident
complications. Pulmonary aspiration can cause signifi-
cant lung disease [6] but is difficult to diagnose clinically
[7]. We sought to discover if pulmonary aspiration was
occurring in a group of clinically stable preschool chil-
dren with CF and, if present, was associated with greater
airway inflammation.
Methods
Clinically stable preschool children with CF undergoing
routine surveillance bronchoscopy were recruited through
the Study of Host Immunity and Early Lung Disease in
Cystic Fibrosis (SHIELD CF). Clinical data were prospect-
ively collected on all children at CF clinic with a standar-
dised clinical information sheet. Non-CF controls were
children without CF undergoing bronchoscopy for clinical
reasons. Informed parental consent was obtained and the
study had ethical approval from the institutional review
board of Our Lady’s Children’s Hospital, Crumlin, Dublin.
Bronchoscopy was performed under general anaesthe-
sia via laryngeal mask airway. Bronchoalveolar lavage
(BAL) samples were obtained by instilling two sequential
aliquots of 1 ml/kg of sterile normal saline per lobe, into
the right middle lobe and lingula (or other affected lobe).
Retrieved samples were then pooled. Differential cell
counts were performed microscopically after staining
with Haematoxylin and Eosin. Pepsin concentrations
were measured in control and CF BAL using a commer-
cial human pepsin ELISA (USCN Life Science Inc.
China). Interleukin 8 (IL-8) was measured in CF BAL by
ELISA as previously described [3]. Neutrophil Elastase
(NE) activity of CF BAL samples was quantified using
the substrate N- (Methoxysuccinyl)-Ala-Ala-Pro-Val
p-nitroanilide as previously described [8]. Differences in
normally distributed data were analysed by Students
t-test, chi squared or Pearson, and non-normally distrib-
uted data with Mann Whitney and Spearman. Signifi-
cance is denoted as a p value < 0.05.* Correspondence: igorman@tcd.ie
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Results
Eighty nine children were included in the study, 77 with
CF [mean age 3.7 years (range 0.86–6.4)] and 12 Control
[3.6 years (1.5–7.8)] (Table 1). No patients had more
than one BAL. BAL pepsin levels were not significantly
different between the groups (385 ± 68.7 pg/ml v. 198 ±
54.2 pg/ml [mean ± SEM]) (Fig. 1a). A subgroup of chil-
dren with CF (18/77 [23%]) had particularly high levels
(high pepsin, > 2 SD above control mean [> 573 pg/ml –
normally distributed data]) compared to all others with
CF (low pepsin). There was no difference in levels of IL-8,
BAL neutrophil counts, proportion with free NE in BAL
or NE levels (where detected) between the high and low
pepsin groups (Fig. 1b, d, e). No associations were found
between BAL levels of pepsin and either IL-8 or NE
(where detected) (Fig. 1c, f ). Recognised CF pathogens (S.
aureus, H. influenza, P. aeruginosa, S. maltophilia) were
found in BAL from 41 of 77(53%) children with CF. There
was no statistically significant difference in the presence of
these organisms, either individually or collectively be-
tween the high and low pepsin groups. There was a low
prevalence of P. aeruginosa (3.9%) and MRSA (1.3%) over-
all within the CF group. There was no significant differ-
ence in any of the gastrointestinal (3/18 and 5/59 with
GOR symptoms [p = 0.136]) or respiratory symptoms re-
lated to pulmonary aspiration or GOR between children
with CF with high and low pepsin levels.
Discussion
We demonstrate in this study that almost 1 in 4 pre-
school children with CF have elevated levels of BAL pep-
sin, suggesting sub-clinical PAGR. In contrast to the
findings of our previous study in older children with CF
[3], in this study there is no evidence that the presence
of pepsin in BAL was associated with pulmonary inflam-
mation. We have little understanding of the natural his-
tory of PAGR in children with CF, particularly as it
relates to frequency of occurrence and variability over
time. PAGR may need to be present for a number of
years before it is associated with recognisable pulmonary
inflammation. This will require further study.
We specifically prospectively collected clinical data on
respiratory and gastrointestinal symptoms (heartburn,
vomiting, post-tussive vomiting, coughing pattern) to
Table 1 Baseline demographics for the study populations
CF (n = 77) Controls (n = 12) p value
Age, mean in years (range) 3.75 (0.86–6.4) 3.6 (1.5–7.8) 0.747
Gender 26F/51M 3F/9M 0.547
BMI, mean (range) 16.6 (15–20.6) 17.6 (16.1–19.7) 0.156
Genotype
F508del Homozygotes 50 N/A N/A
F508del Heterozygotes 17 N/A N/A
Other 10 N/A N/A
Fig. 1 a BAL levels of Pepsin among children with CF and controls (p value 0.81), b IL-8 levels in BAL among those with CF in the high pepsin
and low pepsin groups (p value 0.49), c Correlation between BAL pepsin and BAL IL-8 in children with CF, d Absolute neutrophil count in BAL
among children with CF with high and low pepsin levels (p value 0.31), e Neutrophil elastase (NE) activity in BAL among children with CF with
high and low pepsin levels (p value 0.98), f Correlation between BAL pepsin and BAL NE activity in children with CF
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attempt to determine if there was a recognisable clinical
phenotype associated with PAGR. We found no differ-
ence in symptoms in those with high pepsin levels com-
pared to the rest of the CF group. The diagnosis and
treatment of PAGR is a challenging area. There is likely
a significant overlap between the symptoms of pulmon-
ary aspiration and typical lung disease in CF, and while
it is possible to measure GOR, and to radiologically as-
sess pulmonary aspiration during swallowing, we lack a
specific and sensitive commercially available diagnostic
test for the aspiration of refluxate, the key biological
event of concern. Because we have no available treat-
ment to prevent aspiration of material that refluxes into
the oesophagus or pharynx, treatment for PAGR in-
volves prevention of GOR, which may ultimately entail
fundoplication, not an insignificant undertaking. Proton
pump inhibitors, commonly used in CF, may well
worsen the situation [9, 10].
While it is positive that neither changes in pulmonary
pathogens or pulmonary inflammation were found in
those with PAGR, we have nonetheless discovered a po-
tentially significant biological abnormality that occurs in
a subset of patients. Unfortunately, a perfect biomarker
for pulmonary aspiration does not exist. Longitudinal
BAL pepsin measurements, perhaps in combination with
other previously published PAGR biomarkers such as
bile acids [2], with robust medium term outcome mea-
sures, will be required to determine if early PAGR is as-
sociated with subsequent clinically relevant adverse
outcomes, an approach we plan with this cohort.
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